Gene Expression Profiles of BRCA1-Linked, BRCA2-Linked, and Sporadic Ovarian Cancers

Background: Germline mutations in BRCA1 and BRCA2 are responsible for 5%–10% of epithelial ovarian cancers, but the molecular pathways affected by these mutations are unknown. We used complementary DNA (cDNA) microarrays to compare gene expression patterns in ovarian cancers associated with BRCA1 or...

Full description

Saved in:
Bibliographic Details
Published in:JNCI : Journal of the National Cancer Institute 2002-07, Vol.94 (13), p.990-1000
Main Authors: Jazaeri, Amir A., Yee, Cindy J., Sotiriou, Christos, Brantley, Kelly R., Boyd, Jeff, Liu, Edison T.
Format: Article
Language:English
Subjects:
Adenocarcinoma, Clear Cell - genetics
Adenocarcinoma, Clear Cell - metabolism
Adenocarcinoma, Mucinous - genetics
Adenocarcinoma, Mucinous - metabolism
Aged
Biological and medical sciences
BRCA1 Protein - genetics
BRCA2 Protein - genetics
Carcinoma, Endometrioid - genetics
Carcinoma, Endometrioid - metabolism
Cystadenocarcinoma, Serous - genetics
Cystadenocarcinoma, Serous - metabolism
DNA Primers - chemistry
Female
Female genital diseases
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Genotype
Germ-Line Mutation
Gynecology. Andrology. Obstetrics
Humans
Medical sciences
Middle Aged
Oligonucleotide Array Sequence Analysis
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Reverse Transcriptase Polymerase Chain Reaction
RNA, Messenger - analysis
RNA, Messenger - genetics
RNA, Neoplasm - analysis
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Germline mutations in BRCA1 and BRCA2 are responsible for 5%–10% of epithelial ovarian cancers, but the molecular pathways affected by these mutations are unknown. We used complementary DNA (cDNA) microarrays to compare gene expression patterns in ovarian cancers associated with BRCA1 or BRCA2 mutations with gene expression patterns in sporadic epithelial ovarian cancers and to identify patterns common to both hereditary and sporadic tumors. Methods: Tumor samples from 61 patients with pathologically confirmed epithelial ovarian adenocarcinoma with matched clinicopathologic features were studied, including 18 with BRCA1 founder mutations, 16 with BRCA2 founder mutations, and 27 without either founder mutation (termed sporadic cancers). The cDNA microarrays contained 7651 sequence-verified features. Gene expression data were analyzed with a modified two-sided F test, with P
ISSN:0027-8874
1460-2105
DOI:10.1093/jnci/94.13.990